Results 271 to 280 of about 238,614 (342)
Animal Models and Experimental Medicine, EarlyView.Dietary Qiwenghuangbo powder improved growth performance and intestinal health of weaned piglets, as well as altered microbiota composition as significant enrichment of Limosilactobacillus reuteri. Furthermore, out of three isolated L. reuteri, two strains could alleviate pathogen infection and intestinal inflammation in the colitis models induced by ...
Qian Xu +11 more
wiley +1 more source
Animal Models and Experimental Medicine, EarlyView.Neutrophil‐to‐lymphocyte ratio (NLR) and monocyte‐to‐lymphocyte ratio (MLR) were investigated as potential markers. A total of 3545 subjects were included in the analysis retrospectively. Adult men and women with impaired glucose metabolism were assessed. NLR and MLR may help assess inflammation in individuals with impaired glucose metabolism. Abstract
Ayed A. Dera +11 more
wiley +1 more source
Distinct Alterations of Inflammatory Biomarkers in Cluster Headache: A Case Control Study
Annals of Neurology, EarlyView.Objective Investigate the immune system's role in cluster headache by analyzing cytokines in people with cluster headache and headache‐free controls, and explore if certain cytokines could predict a specific phenotype. Methods We measured 45 cytokines in adult participants from the Danish Cluster Headache Biobank in a prospective case–control setup ...
Nunu Laura Timotheussen Lund +6 more
wiley +1 more source
Annals of Neurology, EarlyView.Objectives Rapid advances in transcriptomics have driven efforts to identify deregulated pathways in multiple sclerosis (MS) tissues, though many detected differentially expressed genes are likely false positives, with only a small fraction reflecting actual pathological events. Robust, integrative methods are essential for accurately understanding the
Gianmarco Abbadessa +11 more
wiley +1 more source
Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology
Angewandte Chemie, EarlyView.Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker +3 more
wiley +2 more sources
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Annals of Neurology, EarlyView.The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr. +2 more
wiley +1 more source
Functional Synovium‐Based 3D Models in the Context of Human Disease and Inflammation
Advanced NanoBiomed Research, EarlyView.The synovium is key to joint function but is often affected by diseases like rheumatoid arthritis. Finding better treatments is challenging because current lab models do not fully mimic real tissues. New 3D technologies, like bioprinting, offer better methods to study these diseases, improve drug testing, and develop personalized treatments, bringing ...
Amelia Heslington +3 more
wiley +1 more source
Animal Research and One Health, EarlyView.Therapeutic effect of natural products on chicken coccidiosis. Abstract The intestinal tract is the main place for animals to digest food and absorb nutrients, which also serves as the first line of defense against pathogens that invade the internal environment.
Pan Chen +6 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective Systemic sclerosis (SSc) is a rare but severe autoimmune disease characterized by immune dysregulation, fibrosis, and vasculopathy. Although previous studies have highlighted the presence of functional autoantibodies targeting the angiotensin II receptor type 1 (AT1) and endothelin‐1 type A receptor (ETAR), leading to autoantibody‐mediated ...
Wieke M. van Oostveen +8 more
wiley +1 more source